Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4 Epitetracycline
2. 4-epitetracycline
3. Achromycin
4. Achromycin V
5. Hostacyclin
6. Sustamycin
7. Tetrabid
8. Tetracycline Hydrochloride
9. Tetracycline Monohydrochloride
10. Topicycline
1. 60-54-8
2. Deschlorobiomycin
3. Tetracyclinum
4. Achromycin
5. Tetracyclin
6. Sumycin
7. Abramycin
8. Tsiklomitsin
9. Cyclopar
10. Ambramycin
11. Liquamycin
12. Panmycin
13. Tetracyn
14. Tetrazyklin
15. Achromycin V
16. Hostacyclin
17. Omegamycin
18. Tetradecin
19. Tetraverine
20. Tsiklomistsin
21. Vetacyclinum
22. Tetrafil
23. Cefracycline
24. Criseociclina
25. Abricycline
26. Agromicina
27. Ambramicina
28. Biocycline
29. Ciclibion
30. Copharlan
31. Democracin
32. Lexacycline
33. Limecycline
34. Mericycline
35. Micycline
36. Orlycycline
37. Polycycline
38. Polyotic
39. Purocyclina
40. Roviciclina
41. Solvocin
42. Tetrabon
43. Tetracycl
44. Amycin
45. Veracin
46. Sk-tetracycline
47. Tetracycline Ii
48. Tetra-co
49. Tetracyclinehydrate
50. Cyclomycin
51. Sumycin Syrup
52. Tetracycline I
53. Bio-tetra
54. (4s,4as,5as,6s,12as)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
55. Tetracycline Base
56. Chebi:27902
57. Piracaps (base)
58. Centet (base)
59. Polycycline (van)
60. (4s,4as,5as,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
61. Nsc-108579
62. Cefracycline Suspension
63. Liquamycin (veterinary)
64. Polycycline (antibiotic)
65. F8vb5m810t
66. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4as,5as,6s,12as)-
67. Tetraciclina
68. Tetracycline (internal Use)
69. Supramycin
70. Vetquamycin-324 (free Base)
71. 60-54-8 (free Base)
72. E701
73. Achromycin (naphthacene Derivative)
74. Nsc 108579
75. T-125
76. Hsdb 3188
77. 6-methyl-1,11-dioxy-2-naphthacenecarboxamide
78. Tetracyclinum [inn-latin]
79. Tetraciclina [inn-spanish]
80. (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
81. Sumycin (tn)
82. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4alpha,4aalpha,5aalpha,6beta,12aalpha))-
83. Unii-f8vb5m810t
84. Economycin
85. Vetquamycin
86. Brodspec
87. Tetracycline (jan/usp/inn)
88. Ccris 9483
89. Sr-01000000212
90. Nsc108579
91. Tetrabid Organon
92. Ala-tet
93. Tetracycline [usp:inn:ban:jan]
94. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-
95. Einecs 200-481-9
96. Mfcd00151232
97. Spectrum_001034
98. Prestwick0_000140
99. Prestwick1_000140
100. Prestwick2_000140
101. Prestwick3_000140
102. Spectrum2_001329
103. Spectrum3_000565
104. Spectrum4_000352
105. Spectrum5_001112
106. Tetracycline [mi]
107. Dsstox_cid_3645
108. Tetracycline [inn]
109. Tetracycline [jan]
110. Ec 200-481-9
111. Tetracycline [hsdb]
112. Schembl3098
113. Dsstox_rid_77127
114. Tetracycline [vandf]
115. Dsstox_gsid_23645
116. Bspbio_000220
117. Bspbio_001950
118. Kbiogr_000783
119. Kbioss_001514
120. Tetracycline [mart.]
121. Bidd:gt0653
122. Divk1c_000827
123. Schembl537050
124. Tetracycline [who-dd]
125. Spbio_001457
126. Spbio_002159
127. Bpbio1_000242
128. Schembl2116649
129. Schembl2116661
130. Dtxsid7023645
131. Schembl21271987
132. Gtpl10927
133. Kbio1_000827
134. Kbio2_001514
135. Kbio2_004082
136. Kbio2_006650
137. Kbio3_001450
138. Tetracycline [green Book]
139. Ninds_000827
140. Hms2090b04
141. Tetracycline [orange Book]
142. Tetracycline, >=98.0% (nt)
143. Tetracycline [ep Monograph]
144. Tetracycline [usp Impurity]
145. 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-
146. Hy-a0107
147. Pylera Component Tetracycline
148. Rkl10088
149. Tetracycline [usp Monograph]
150. Tetracycline, >=88.0% (hplc)
151. Tox21_300150
152. Bdbm50237605
153. S4490
154. Zinc84441937
155. Akos024277860
156. Akos026749977
157. Zinc100303069
158. Zinc102229720
159. Cs-8188
160. Db00759
161. Tetracycline Component Of Pylera
162. Cas-60-54-8
163. Idi1_000827
164. Ncgc00017323-03
165. Ncgc00017323-04
166. Ncgc00017323-05
167. Ncgc00017323-07
168. Ncgc00017323-15
169. Ncgc00142507-02
170. Ncgc00254063-01
171. 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,1 0,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
172. Bt166207
173. Sbi-0051530.p003
174. Lymecycline Impurity H [ep Impurity]
175. T3971
176. C06570
177. D00201
178. Ab00053550-04
179. Ab00053550_05
180. Ab00053550_06
181. Q193045
182. Sr-01000000212-3
183. Z2144222809
184. Oxytetracycline Hydrochloride Impurity B [ep Impurity]
185. (4r,4as,5as,6s,12as)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
186. (4s,4as,5as,6s,12as)-2-[amino(hydroxy)methylene]-4beta-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,12a-decahydro-6alpha,10,12,12abeta-tetrahydroxy-6-methylnaphthacene-1,3,11-trione
187. (4s,4as,5as,6s,12as)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
| Molecular Weight | 444.4 g/mol |
|---|---|
| Molecular Formula | C22H24N2O8 |
| XLogP3 | -2 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 2 |
| Exact Mass | 444.15326573 g/mol |
| Monoisotopic Mass | 444.15326573 g/mol |
| Topological Polar Surface Area | 182 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 971 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Achromycin v |
| Drug Label | Tetracycline is a yellow, odorless, crystalline powder. Tetracycline is stable in air but exposure to strong sunlight causes it to darken. Its potency is affected in solutions of pH below 2 and is rapidly destroyed by alkali hydroxide solutions. Tetr... |
| Active Ingredient | Tetracycline hydrochloride |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 250mg; 500mg |
| Market Status | Prescription |
| Company | Heritage Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Achromycin v |
| Drug Label | Tetracycline is a yellow, odorless, crystalline powder. Tetracycline is stable in air but exposure to strong sunlight causes it to darken. Its potency is affected in solutions of pH below 2 and is rapidly destroyed by alkali hydroxide solutions. Tetr... |
| Active Ingredient | Tetracycline hydrochloride |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 250mg; 500mg |
| Market Status | Prescription |
| Company | Heritage Pharms |
Antibiotics, Tetracycline; Protein Synthesis Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Tetracycline hydrochloride ointment is used in the prophylaxis of minor bacterial skin infections and in the treatment of dermal ulcer. /Tetracycline hydrochloride; NOT included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 2818
Tetracycline hydrochloride ointment is indicated in the topical treatment of minor skin infections caused by streptococci, staphylococci, and other susceptible organisms. /Tetracycline hydrochloride; Included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 2818
Tetracycline hydrochloride for topical solution is indicated for the topical treatment of acne vulgaris. It may be effective in grades II and III acne, which are characterized by inflammatory lesions such as papules and pustules. /Tetracycline hydrochloride; Included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 2818
For more Therapeutic Uses (Complete) data for TETRACYCLINE (37 total), please visit the HSDB record page.
EXCEPT FOR LOCAL USE IN EYE, TOPICAL USE OF TETRACYCLINES IS NOT RECOMMENDED. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1127
MICROORGANISMS THAT HAVE BECOME INSENSITIVE TO ONE TETRACYCLINE FREQUENTLY EXHIBIT RESISTANCE TO OTHERS. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1126
CROSS-SENSITIZATION AMONG VARIOUS TETRACYCLINES IS COMMON . /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1130
... NAUSEA, VOMITING, POLYURIA, POLYDIPSIA, PROTEINURIA, ACIDOSIS, GLYCOSURIA, & GROSS AMINOACIDURIA, A FORM OF FANCONI SYNDROME, HAS BEEN OBSERVED IN PT INGESTING OUTDATED, & DEGRADED TETRACYCLINE.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1130
For more Drug Warnings (Complete) data for TETRACYCLINE (31 total), please visit the HSDB record page.
Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.
Tetracycline is a short-acting antibiotic that inhibits bacterial growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. It also binds to some extent to the 50S ribosomal subunit. This binding is reversible in nature. Additionally tetracycline may alter the cytoplasmic membrane of bacteria causing leakage of intracellular contents, such as nucleotides, from the cell.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
D06AA04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A01 - Stomatological preparations
A01A - Stomatological preparations
A01AB - Antiinfectives and antiseptics for local oral treatment
A01AB13 - Tetracycline
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06A - Antibiotics for topical use
D06AA - Tetracycline and derivatives
D06AA04 - Tetracycline
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01A - Tetracyclines
J01AA - Tetracyclines
J01AA07 - Tetracycline
S - Sensory organs
S01 - Ophthalmologicals
S01A - Antiinfectives
S01AA - Antibiotics
S01AA09 - Tetracycline
S - Sensory organs
S02 - Otologicals
S02A - Antiinfectives
S02AA - Antiinfectives
S02AA08 - Tetracycline
S - Sensory organs
S03 - Ophthalmological and otological preparations
S03A - Antiinfectives
S03AA - Antiinfectives
S03AA02 - Tetracycline
Absorption
Bioavailability is less than 40% when administered via intramuscular injection, 100% intravenously, and 60-80% orally (fasting adults). Food and/or milk reduce GI absorption of oral preparations of tetracycline by 50% or more.
Route of Elimination
They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.
ALL TETRACYCLINES ARE ADEQUATELY BUT INCOMPLETELY ABSORBED FROM GI TRACT. MOST ABSORPTION TAKES PLACE FROM STOMACH & UPPER SMALL INTESTINE & IS GREATEST IN FASTING STATE. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1126
... /TETRACYCLINE IS/ VERY INCOMPLETELY ABSORBED. AFTER SINGLE ORAL DOSE PEAK PLASMA CONCN ARE ATTAINED IN 2-4 HR. ... ADMIN OF 250 MG EVERY 6 HR PRODUCES PEAK PLASMA CONCN OF APPROX 2-2.5 UG/ML.
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1126
THE PRIMARY ROUTE OF ELIMINATION FOR MOST TETRACYCLINES IS THE KIDNEY, ALTHOUGH THEY ARE ALSO CONCENTRATED IN THE LIVER AND EXCRETED BY ... BILE, INTO INTESTINE, FROM WHICH THEY ARE PARTIALLY REABSORBED. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1126
ELIMINATION FROM INTESTINAL TRACT OCCURS EVEN WHEN DRUGS ARE GIVEN PARENTERALLY, AS RESULT OF EXCRETION IN BILE. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1123
For more Absorption, Distribution and Excretion (Complete) data for TETRACYCLINE (16 total), please visit the HSDB record page.
Not metabolized
6-12 hours
/IT HAS HALF-LIFE/ IN RANGE OF 6-12 HR...
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1126
Tetracycline was encapsulated in erythrocytes by a dialysis technique. On encapsulation of (14)C sucrose and (3)H tetracycline, the drug concn (0.2 mg/ml of erythrocytes) decreased the tetracycline encapsulation, but not (14)C sucrose. Carrier erythrocytes containing tetracycline reinjected in calves were studied for their pharmacokinetic constants. the drug half-life was 6.7 hr with an overall elimination constant of 0.104 hr.
PMID:6731978 DeLoach JR, Wagner GG; Am J Vet Res 45 (4): 640-642 (1984)
The serum half-life...is 6-12 hr in adults with normal renal funtion and is reported to be 57-120 hr in patients with severe renal impairment.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1997 (Plus Supplements)., p. 385
Tetracycline passively diffuses through porin channels in the bacterial membrane and reversibly binds to the 30S ribosomal subunit, preventing binding of tRNA to the mRNA-ribosome complex, and thus interfering with protein synthesis.
TETRACYCLINES ARE THOUGHT TO INHIBIT PROTEIN SYNTH BY BINDING SPECIFICALLY TO 30 S RIBOSOMES AND PREVENTING ACCESS OF AMINOACYL TRNA TO... MRNA-RIBOSOME COMPLEX. /TETRACYCLINES/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1125
... IT IS POSSIBLE THAT REVERSIBLY BOUND ANTIBIOTIC IS RESPONSIBLE FOR ANTIBACTERIAL ACTION. /TETRACYCLINES/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1185
TETRACYCLINE COMBINES WITH CELLULAR & INTRACELLULAR MATERIAL TO FORM A FLUOROPHORE WHICH UNDER UV LIGHT GLOWS WITH YELLOW-GOLD FLUORESCENCE. THE FLUOROPHORE REMAINS IN BONE FOR MANY MO.
Thienes, C., and T.J. Haley. Clinical Toxicology. 5th ed. Philadelphia: Lea and Febiger, 1972., p. 141
PHOTOALLERGIC REACTIONS ARE BELIEVED TO RESULT FROM LIGHT ENERGY ACTING ON OR ALTERING DRUG & SKIN PROTEINS IN SUCH MANNER AS TO FORM AN ANTIGEN. THESE ERUPTIONS REQUIRE PREVIOUS CONTACT WITH OFFENDING SUBSTANCE, ARE NOT DOSE-RELATED, & EXHIBIT CROSS-SENSITIVITY WITH CHEM RELATED COMPD. /TETRACYCLINES/
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1276
For more Mechanism of Action (Complete) data for TETRACYCLINE (6 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
31
PharmaCompass offers a list of Tetracycline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tetracycline manufacturer or Tetracycline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tetracycline manufacturer or Tetracycline supplier.
PharmaCompass also assists you with knowing the Tetracycline API Price utilized in the formulation of products. Tetracycline API Price is not always fixed or binding as the Tetracycline Price is obtained through a variety of data sources. The Tetracycline Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A PYLERA-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of PYLERA-2, including repackagers and relabelers. The FDA regulates PYLERA-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. PYLERA-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of PYLERA-2 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A PYLERA-2 supplier is an individual or a company that provides PYLERA-2 active pharmaceutical ingredient (API) or PYLERA-2 finished formulations upon request. The PYLERA-2 suppliers may include PYLERA-2 API manufacturers, exporters, distributors and traders.
click here to find a list of PYLERA-2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A PYLERA-2 DMF (Drug Master File) is a document detailing the whole manufacturing process of PYLERA-2 active pharmaceutical ingredient (API) in detail. Different forms of PYLERA-2 DMFs exist exist since differing nations have different regulations, such as PYLERA-2 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A PYLERA-2 DMF submitted to regulatory agencies in the US is known as a USDMF. PYLERA-2 USDMF includes data on PYLERA-2's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The PYLERA-2 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of PYLERA-2 suppliers with USDMF on PharmaCompass.
PYLERA-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of PYLERA-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right PYLERA-2 GMP manufacturer or PYLERA-2 GMP API supplier for your needs.
A PYLERA-2 CoA (Certificate of Analysis) is a formal document that attests to PYLERA-2's compliance with PYLERA-2 specifications and serves as a tool for batch-level quality control.
PYLERA-2 CoA mostly includes findings from lab analyses of a specific batch. For each PYLERA-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
PYLERA-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (PYLERA-2 EP), PYLERA-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (PYLERA-2 USP).
